Connection

SETH LERNER to Apoptosis

This is a "connection" page, showing publications SETH LERNER has written about Apoptosis.
Connection Strength

0.227
  1. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer. 2013 Feb; 4(1):24-35.
    View in: PubMed
    Score: 0.063
  2. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol. 2009 Jul-Aug; 27(4):391-9.
    View in: PubMed
    Score: 0.047
  3. Molecular markers in bladder cancer. Curr Opin Urol. 2008 Jan; 18(1):1-8.
    View in: PubMed
    Score: 0.046
  4. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015 Jan 08; 517(7533):209-13.
    View in: PubMed
    Score: 0.018
  5. The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3383-9.
    View in: PubMed
    Score: 0.018
  6. A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma. Urol Oncol. 2013 Feb; 31(2):234-40.
    View in: PubMed
    Score: 0.015
  7. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther. 2009 Jul; 8(7):1772-8.
    View in: PubMed
    Score: 0.013
  8. Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. J Urol. 2001 Oct; 166(4):1316-21.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.